ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1639

A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants

Yusuf Yazici1, Christopher Swearingen2, Heli Ghandehari3, Jon Britt4, ismail simsek5, Mark Fineman6, Sarah Kennedy2, Jeyanesh Tambiah7 and Timothy McAlindon8, 1New York University School of Medicine, La Jolla, CA, 2Biosplice Therapeutics, Inc, San Diego, CA, 3Biosplice Therapeutics, Inc., San Diego, CA, 4Biosplice Therapeutics, Inc., Los Angeles, CA, 5Alpine Immunesciences, San Diego, CA, 6Biosplice Therapeutics, San Diego, CA, 7Biosplice Ther Inc., San Diego, CA, 8Tufts Medical Center, Arlington, MA

Meeting: ACR Convergence 2022

Keywords: clinical trial, Osteoarthritis, pain

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Osteoarthritis – Clinical

Session Type: Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Knee osteoarthritis (OA) is a common joint disorder associated with pain, disability, and joint damage. There remains a large unmet need for treatments that are safe and efficacious for treatment of signs and symptoms and structure modification. Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, has previously appeared safe and demonstrated patient-reported outcome (PRO) improvements compared with placebo (PBO) and maintenance of medial joint space width (mJSW). The safety and efficacy of LOR was evaluated in a 56-week trial (OA-11, NCT03928184) utilizing PRO and radiographic outcomes.

Methods: Participants were randomized 1:1 to receive a single IA injection of 2 mL 0.07 mg LOR (n=249) or vehicle PBO (n=252). Enrolled participants had ACR-defined (clinical and radiographic) knee OA, Kellgren-Lawrence (KL) grades 2-3, and Pain Numeric Rating Scale (NRS) [0-10] ≥4 and ≤8 in the target knee and < 4 in the contralateral knee. To enrich for participants who may show structural progression, OA-11 allowed BMI up to 40 and restricted enrollment to those with baseline mJSW [1.5-4.0] mm. Primary endpoint was change from baseline in Pain NRS at week 12. Additional outcomes included change from baseline in WOMAC Function [0-100], WOMAC Pain [0-100], Patient Global Assessment (PtGA) [0-100], and mJSW. Adverse events (AEs) were collected throughout the trial. Change from baseline was estimated using a mixed-effects model for repeated measures with treatment group, week, treatment×week, and baseline as covariates.

Results: 501 participants (mean age 60.9 ± 8.3 years, BMI 31.5 ± 4.7 kg/m2, female 65.5%, KL2 51.5%, 67.7% bilaterally symptomatic, mean baseline mJSW 2.61±0.72 mm) enrolled. The trial did not meet its primary endpoint. At week 12, change from baseline in Pain NRS was LOR -2.20 ± 2.20 vs. PBO-2.58 ± 2.24, NS. There were no meaningful treatment effects observed between LOR and PBO in any FAS PROs. Despite enrichment for progression, neither group showed mJSW narrowing over 52 weeks, PBO -0.07 ± 0.50 vs. LOR -0.10 ± 0.52, NS. 307 AEs were reported in 127 PBO participants and 311 AEs were reported in 136 LOR participants. There were 15 SAEs in 12 LOR and 19 SAEs in 13 PBO; no SAEs were deemed treatment related.

Conclusion: LOR appeared safe and well tolerated but did not meet the primary endpoint of change from baseline in Pain NRS at week 12 in this trial. Multiple potential reasons for discrepancies between this and other LOR trials were identified. These participants had the most structurally advanced disease enrolled in the program to date, with baseline mJSW < 3 mm for 68%. As is the case with most chronic conditions, earlier intervention may be more effective, and these more severe subjects may require higher or more frequent dosing. This trial was conducted during the COVID pandemic, and while its impact was difficult to quantify, effects on activity levels and pain PROs in knee OA patients have been reported (Larghi et al., Acta Biomed 2020; Endstrasser et al., ESSKA 2020). These participants are being followed for an additional year (OA-07) to evaluate the effects of a second dose on PROs, as well as longer duration to evaluate structural progression.


Disclosures: Y. Yazici, Amgen, Biosplice; C. Swearingen, Biosplice Therapeutics, Inc; H. Ghandehari, Biosplice Therapeutics, Inc.; J. Britt, Biosplice Therapeutics; i. simsek, Biosplice Inc.; M. Fineman, Biosplice Therapeutics; S. Kennedy, Biosplice Therapeutics, Inc; J. Tambiah, Biosplice Therapeutics; T. McAlindon, Biosplice Therapeutics, Inc, Remedium-Bio, Organogenesis, Pfizer, Kolon Tissue Gene, Seikugaku.

To cite this abstract in AMA style:

Yazici Y, Swearingen C, Ghandehari H, Britt J, simsek i, Fineman M, Kennedy S, Tambiah J, McAlindon T. A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo Controlled Trial (OA-11) to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint Injected in the Target Knee Joint of Moderate to Severe Osteoarthritis Participants [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/a-phase-3-56-week-multicenter-randomized-double-blind-placebo-controlled-trial-oa-11-to-evaluate-the-efficacy-and-safety-of-a-single-injection-of-lorecivivint-injected-in-the-target-knee-joint/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-phase-3-56-week-multicenter-randomized-double-blind-placebo-controlled-trial-oa-11-to-evaluate-the-efficacy-and-safety-of-a-single-injection-of-lorecivivint-injected-in-the-target-knee-joint/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology